New Treatment Options in the Management of Relapsed/Refractory Hodgkin Lymphoma
This information was originally presented on September 14, 2012, at the NCCN 7th Annual Congress: Hematologic Malignancies™ held in New York, New York.
This activity is designed to meet the educational needs of hematologists, oncologists, nurses, pharmacists, and other health care professionals who manage patients with hematologic malignancies.
Following this activity, participants should be able to:
- Discuss the current treatment options for the management of patients with relapsed or refractory HL
- Identify the rationale and need for the development of more effective treatment options for patients with relapsed/refractory HL
- Review the clinical evidence from ongoing trials evaluating novel treatment options and the potential role of new agents in the treatment algorithm of HL
Leo I. Gordon, MD
Robert H. Lurie Comprehensive Cancer Center of Northwestern University
- 0.75 Participation
- 0.71 Nurse
- 0.75 Pharmacist
- 0.75 Physician